| Authors | Mintzes B |
|---|
| Source | PLoS Med 2006;3(4):e198. |
|---|
| Abstract | Ray Moynihan and colleagues describe disease mongering as, 'widening the boundaries of treatable illness in order to expand markets for those who sell and deliver treatments'. In this article, I examine one aspect of disease mongering: activities financed by drug companies to promote sales by expanding the pool of patients potentially treated by their products, when no benefit in terms of reduced morbidity is likely. New diseases may be “created” or existing conditions redefined. In theory, these activities are covered by national laws governing drug promotion that forbid misleading or deceptive advertising. However, enforcement is piecemeal and largely ineffective. |
|---|
| Code | CHSPR 06:08R |
|---|
Visit Journal or Publisher Web Site
